智通财经APP获悉，维立志博-B(09887)再涨近6%，截至发稿，涨4.63%，报62.2港元，成交额1142.28万港元。
消息面上，维立志博宣布，公司基于专有TCE技术平台LeadsBody自主研发的GPRC5D/CD3双特异性抗体LBL-034，获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，用于治疗复发/难治性多发性骨髓瘤（RRMM）。
这是继2024年10月获FDA孤儿药认定后，该产品在国际化开发道路上的又一重要里程碑，标志着其临床价值与开发策略进一步获得国际监管机构的认可。据悉，LBL-034是一款靶向GPRC5D及CD3的人源化双特异性T细胞衔接器。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.